Skip to main content
Premium Trial:

Request an Annual Quote

Biogen Signs On to Buy More EST Antibodies from MorphoSys

NEW YORK, Jan. 8 — MorphoSys said Tuesday that it would expand its drug target identification and validation partnership with Cambridge, Mass.-based Biogen.


Under the two companies' initial agreement, inked one year ago, MorphoSys provides Biogen with research antibodies against expressed sequence tags for drug target validation. The new agreement increases the number of ESTs in the deal, and allows Biogen access to MorphoSys' new HuCAL GOLD library.

Through the old partnership, Biogen paid MorphoSys an upfront technology access fee and for use of the HuCAL technology. Biogen also agreed to make milestone and royalty payments for any antibody-based therapeutics.


By this updated agreement, MorphoSys will receive additional research and licensing payments. Financial details were not disclosed.


Munich-based MorphoSys develops technologies for synthetic antibody production and produces human antibodies for use in drug development.


Biogen will be the first partner to access this version of the MorphoSys library, said the company.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.